Holen Sie sich die Stockscreener-App
9.05
3.31%
0.30
Schlusskurs vom Vortag:
$8.75
Offen:
$8.77
24-Stunden-Volumen:
371.35K
Relative Volume:
2.11
Marktkapitalisierung:
$437.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-76.41M
KGV:
-4.525
EPS:
-2
Netto-Cashflow:
$-64.56M
1W Leistung:
-9.33%
1M Leistung:
-22.40%
6M Leistung:
+30.07%
1J Leistung:
+13.14%
1-Tages-Spanne:
$8.71
$9.09
1-Wochen-Bereich:
$8.71
$10.16
52-Wochen-Spanne:
$6.63
$12.38
Aura Biosciences Inc Stock (AURA) Company Profile
Firmenname
Aura Biosciences Inc
Sektor
Branche
Telefon
(617)500-8864
Adresse
80 GUEST STREET, BOSTON
Vergleichen Sie AURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| AURA | 9.07 | 437.08M | 0 | -76.41M | -64.56M | -2.00 |
| VRTX | 449.64 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.75 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.13 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.53 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2022-07-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Aktie (AURA) Neueste Nachrichten
Aura Biosciences' chief medical officer sells $110,663 in stock - Investing.com
HC Wainwright Forecasts Higher Earnings for Aura Biosciences - Defense World
HC Wainwright Has Bullish Forecast for AURA FY2024 Earnings - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update - MarketBeat
Aura Biosciences’ (AURA) Buy Rating Reiterated at HC Wainwright - Defense World
What is Leerink Partnrs’ Estimate for AURA FY2024 Earnings? - Defense World
Leerink Partnrs Has Strong Forecast for AURA FY2024 Earnings - MarketBeat
Citadel Advisors LLC Reduces Stake in Aura Biosciences Inc - GuruFocus.com
Brokerages Set Aura Biosciences, Inc. (NASDAQ:AURA) Target Price at $23.00 - Defense World
HC Wainwright Reaffirms Buy Rating for Aura Biosciences (NASDAQ:AURA) - MarketBeat
Aura Biosciences Reports Q3 Financial Results - TipRanks
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study - MSN
Aura Biosciences : Reports Third Quarter 2024 Financial Results and Business Highlights Form 8 K - Marketscreener.com
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of "Buy" from Analysts - MarketBeat
One Aura Biosciences Insider Raised Stake By 232% In Previous Year - Yahoo Finance
Short Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Decreases By 8.7% - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $98,808.00 in Stock - MarketBeat
Aura Biosciences VP sells shares worth $5,938 By Investing.com - Investing.com Australia
Aura Biosciences CEO Elisabet de los Pinos sells $98,787 in stock By Investing.com - Investing.com South Africa
Aura Biosciences CEO Elisabet de los Pinos sells $98,787 in stock - Investing.com
Aura Biosciences VP sells shares worth $5,938 - Investing.com
Don't Ignore The Insider Selling In Aura Biosciences - Simply Wall St
Aura Biosciences (NASDAQ:AURA) Stock Price Down 4.9% After Insider Selling - Defense World
Aura Biosciences CFO Julie Feder sells shares worth $302,361 - Investing.com India
Aura Biosciences (NASDAQ:AURA) Trading Down 4.9% on Insider Selling - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) CFO Sells $302,325.93 in Stock - MarketBeat
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value - Seeking Alpha
Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Average Price Target from Analysts - Defense World
Long Term Trading Analysis for (AURA) - Stock Traders Daily
Aura Biosciences (NASDAQ:AURA) PT Raised to $22.00 at HC Wainwright - Defense World
Aura Biosciences stock hits 52-week high at $12.38 By Investing.com - Investing.com Australia
Aura Biosciences CEO sells $300,838 in stock By Investing.com - Investing.com Australia
Aura Biosciences reports promising early trial results - Investing.com India
Insider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells 24,992 Shares of Stock - MarketBeat
Aura Biosciences CEO sells $300,838 in stock - Investing.com
Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Aura Biosciences' Shares Touch 52-Week High on Positive Cancer Drug Data - MarketWatch
Aura Biosciences (NASDAQ:AURA) Hits New 12-Month High After Analyst Upgrade - MarketBeat
Aura Biosciences stock hits 52-week high at $12.38 - Investing.com
Aura Biosciences stock maintains Buy rating on promising trial results By Investing.com - Investing.com Canada
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease - Benzinga
Aura Biosciences (NASDAQ:AURA) Price Target Increased to $23.00 by Analysts at Scotiabank - MarketBeat
Aura Biosciences stock price target up 5%, H.C. Wainwright rates Buy after virtual oncology event - Investing.com Canada
Aura Biosciences Shares Surge After-Hour On Positive Clinical Trial Results - Stocks Telegraph
Multiple Clinical Complete Responses Demonstrated Following - GlobeNewswire
Aura Biosciences Reports Positive Phase 1 Trial Results - TipRanks
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial - The Manila Times
Aura Biosciences reports promising early trial results By Investing.com - Investing.com UK
Finanzdaten der Aura Biosciences Inc-Aktie (AURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):